3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Leukemia, Biphenotypic, Acute
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
8
Fluorouracil
8
Nivolumab
7
Leucovorin
7
Paclitaxel
6
Capecitabine
5
Taxes
4
Specimen Handling
4
pembrolizumab
3
Trastuzumab
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Cisplatin
3
zimberelimab
2
zanidatamab
2
Radiotherapy
2
Folfox protocol
2
Carboplatin
2
zolbetuximab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
quemliclustat
1
obeticholic acid
1
futibatinib
1
dehydroftorafur
1
cixutumumab
1
balstilimab
1
Saline Solution
1
Radiofrequency Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
Levoleucovorin
×
30 days
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled